|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
33,620,000 |
Market
Cap: |
110.27(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$1.295 - $6.09 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Aquestive Therapeutics is a pharmaceutical company. Co. is developing orally administered products to deliver various molecules using its proprietary technologies, PharmFilm®. Co.'s products within its central nervous system portfolio, focused on epilepsy, include: Sympazan®, an oral soluble film formulation of clobazam used for the treatment of seizures associated with a rare, intractable form of epilepsy known as Lennox-Gastaut syndrome; and Libervant, a buccally, or inside of the cheek, administered soluble film formulation of diazepam, used as an alternative to device-dependent rescue therapies, available to patients with refractory epilepsy, which are a rectal gel and nasal sprays.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
158,668 |
Total Buy Value |
$0 |
$0 |
$0 |
$151,571 |
Total People Bought |
0 |
0 |
0 |
4 |
Total Buy Transactions |
0 |
0 |
0 |
5 |
Total Shares Sold |
75,000 |
75,000 |
75,000 |
75,000 |
Total Sell Value |
$429,685 |
$429,685 |
$429,685 |
$429,685 |
Total People Sold |
1 |
1 |
1 |
1 |
Total Sell Transactions |
2 |
2 |
2 |
2 |
End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Kendall Keith J |
CEO and President |
|
2020-06-30 |
4 |
D |
$4.86 |
$719 |
D/D |
(148) |
639,149 |
|
- |
|
Kendall Keith J |
CEO and President |
|
2020-06-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
333 |
639,297 |
|
- |
|
Kendall Keith J |
CEO and President |
|
2020-06-04 |
4 |
AS |
$5.11 |
$255,310 |
D/D |
(50,000) |
638,964 |
|
-3% |
|
Schobel Alexander Mark |
Chief Innovation/Tech Officer |
|
2020-05-31 |
4 |
D |
$4.87 |
$20,123 |
D/D |
(4,132) |
912,553 |
|
- |
|
Schobel Alexander Mark |
Chief Innovation/Tech Officer |
|
2020-05-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
14,572 |
916,685 |
|
- |
|
Kendall Keith J |
CEO and President |
|
2020-05-31 |
4 |
D |
$4.87 |
$31,616 |
D/D |
(6,492) |
688,964 |
|
- |
|
Kendall Keith J |
CEO and President |
|
2020-05-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
14,572 |
695,456 |
|
- |
|
Schobel Alexander Mark |
Chief Innovation/Tech Officer |
|
2020-05-08 |
4 |
AS |
$5.00 |
$200,000 |
D/D |
(40,000) |
902,113 |
|
76% |
|
Schobel Alexander Mark |
Chief Innovation/Tech Officer |
|
2020-04-29 |
4 |
AS |
$4.50 |
$180,000 |
D/D |
(40,000) |
1,022,113 |
|
77% |
|
Schobel Alexander Mark |
Chief Innovation/Tech Officer |
|
2020-04-27 |
4 |
AS |
$4.00 |
$160,000 |
D/D |
(40,000) |
942,113 |
|
74% |
|
Schobel Alexander Mark |
Chief Innovation/Tech Officer |
|
2020-04-14 |
4 |
AS |
$3.70 |
$148,000 |
D/D |
(40,000) |
982,113 |
|
184% |
|
Kendall Keith J |
CEO and President |
|
2020-03-31 |
4 |
D |
$2.19 |
$217 |
D/D |
(99) |
680,884 |
|
- |
|
Kendall Keith J |
CEO and President |
|
2020-03-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
329 |
680,983 |
|
- |
|
Schobel Alexander Mark |
Chief Innovation/Tech Officer |
|
2020-03-31 |
4 |
D |
$2.19 |
$212 |
D/D |
(97) |
1,062,113 |
|
- |
|
Schobel Alexander Mark |
Chief Innovation/Tech Officer |
|
2020-03-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
329 |
1,062,210 |
|
- |
|
Braender Lori J |
SVP, General Counsel |
|
2020-03-16 |
4 |
B |
$1.54 |
$21,624 |
D/D |
14,000 |
25,000 |
0.01 |
231% |
|
Boyd Peter E. |
SVP-Bus. Process & Info. Tech. |
|
2020-03-16 |
4 |
B |
$1.50 |
$3,000 |
D/D |
2,000 |
52,239 |
0.01 |
231% |
|
Schobel Alexander Mark |
Chief Innovation/Tech Officer |
|
2020-02-29 |
4 |
D |
$3.73 |
$18,896 |
D/D |
(5,066) |
1,061,881 |
|
- |
|
Schobel Alexander Mark |
Chief Innovation/Tech Officer |
|
2020-02-29 |
4 |
OE |
$0.00 |
$0 |
D/D |
14,572 |
1,066,947 |
|
- |
|
Kendall Keith J |
CEO and President |
|
2020-02-29 |
4 |
D |
$3.73 |
$17,639 |
D/D |
(4,729) |
680,654 |
|
- |
|
Kendall Keith J |
CEO and President |
|
2020-02-29 |
4 |
OE |
$0.00 |
$0 |
D/D |
14,572 |
685,383 |
|
- |
|
Kendall Keith J |
CEO and President |
|
2019-12-31 |
4/A |
D |
$5.82 |
$867 |
D/D |
(149) |
670,811 |
|
- |
|
Schobel Alexander Mark |
Chief Innovation/Tech Officer |
|
2019-12-31 |
4/A |
D |
$5.82 |
$856 |
D/D |
(147) |
1,052,375 |
|
- |
|
Schobel Alexander Mark |
Chief Innovation/Tech Officer |
|
2019-12-31 |
4 |
D |
$5.82 |
$1,915 |
D/D |
(329) |
1,044,165 |
|
- |
|
Schobel Alexander Mark |
Chief Innovation/Tech Officer |
|
2019-12-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
329 |
1,044,494 |
|
- |
|
147 Records found
|
|
Page 3 of 6 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|